Kiniksa Pharmaceuticals International, plc $KNSA Shares Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC boosted its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 48.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 129,250 shares of the company’s stock after buying an additional 41,945 shares during the quarter. Kiniksa Pharmaceuticals International accounts for approximately 2.6% of Lisanti Capital Growth LLC’s holdings, making the stock its 3rd biggest position. Lisanti Capital Growth LLC’s holdings in Kiniksa Pharmaceuticals International were worth $9,643,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Rubric Capital Management LP grew its stake in shares of Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after acquiring an additional 421,347 shares during the period. Pictet Asset Management Holding SA lifted its position in Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after purchasing an additional 251,578 shares during the period. Dimensional Fund Advisors LP lifted its position in Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after purchasing an additional 128,417 shares during the period. Spruce Street Capital LP lifted its position in Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after purchasing an additional 326,081 shares during the period. Finally, Bank of America Corp DE boosted its holdings in Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after purchasing an additional 506,576 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Up 0.8%

Shares of NASDAQ:KNSA opened at $95.76 on Thursday. The firm’s 50 day moving average price is $81.53 and its 200-day moving average price is $62.18. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $99.31. The stock has a market capitalization of $7.52 billion, a PE ratio of 73.66 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on KNSA shares. The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. JPMorgan Chase & Co. increased their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Citigroup raised their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Finally, Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.57.

Insiders Place Their Bets

In other news, CAO Michael R. Megna sold 36,260 shares of the company’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $94.43, for a total value of $3,424,031.80. Following the completion of the sale, the chief accounting officer directly owned 12,697 shares in the company, valued at $1,198,977.71. This represents a 74.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 77,587 shares of the firm’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $93.02, for a total value of $7,217,142.74. Following the completion of the transaction, the insider directly owned 69,922 shares in the company, valued at approximately $6,504,144.44. This represents a 52.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 831,022 shares of company stock valued at $77,475,599. 51.98% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.